ESC Professional Premium Access

Cost impact of the ESC/EAS 2019 dyslipidemia guidelines recommended use of PSCK9i in very-high-risk patients with an LDL <1.8mmol/L for secondary prevention

Congress Presentation

About the speaker

Doctor Max Waters

University Hospital Limerick, Limerick (Ireland)
0 follower

8 more presentations in this session

Hyperlipoproteinemia(a) in coronary artery disease patients: who are patients with very high levels and how do they respond to the PCSK9 antibody therapy?

Speaker: Doctor M. Novakovic (Ljubljana, SI)


Prevalence and outcomes of familial hypercholesterolemia in young patients undergoing coronary bypass surgery

Speaker: Doctor J. Black (Hobart, AU)


Increased triglyceride independently associates with premature structural and functional cardiac damage progression in asymptomatic adolescents: a 7-year longitudinal study

Speaker: Doctor A. Agbaje (Kuopio, FI)


Characterization of lipidic coronary atheroma under control of low-density lipoprotein <1.8 mmol/l and lipoprotein (a) <50 mg/dl in patients with coronary artery disease

Speaker: Doctor D. Shishikura (Takatsuki, JP)


Increased Lipoprotein (a) and familial hypercholesterolemia: a dangerous combination.Data from a 12-year follow-up study

Speaker: Doctor I. Andrikou (Athens, GR)


Access the full session

Risk factors and prevention: lipids (2)

Speakers: Doctor M. Waters, Doctor M. Novakovic, Doctor J. Black, Doctor A. Agbaje, Doctor D. Shishikura...

About the event


ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb